Wholesale Drug Distributor and Third-Party Logistics Licensing Readiness

By Thomas G. Goddard, JD, PhD, former Chief Operating Officer and General Counsel of URAC

Last updated: November 2026

Wholesale drug distributor and third-party logistics (3PL) licensing readiness helps start-up owners prepare the documents, procedures and records for applicable human-prescription-drug licensing requirements. Integral Healthcare Solutions (IHS) assesses gaps and drafts materials for owner and counsel review. The owner handles submissions.

What does federal law require before a distributor or 3PL ships?

Until the wholesale distributor licensing regulations take effect, 21 U.S.C. 360eee-1(a)(6) says “licensed” or “authorized,” for a wholesale distributor with respect to prescription drugs, means a wholesale distributor with a valid license under State law. The framework in 21 U.S.C. 353(e)(1)(A) calls for a license from the State the drug is distributed from, or from the Secretary of Health and Human Services if that State has not established a licensure requirement, plus the State distributed into if the drug moves interstate and that State requires licensure of a person that distributes drugs into it. FDA’s regulations are still proposed (below), so counsel confirms whether any federal license is available today (U.S. Code text through October 9, 2026; pages opened November 5, 2026).

21 CFR Part 205—Guidelines for State Licensing of Wholesale Prescription Drug Distributors (current eCFR file built November 4, 2026; page opened November 5, 2026) is the older text. Section 205.4 says every wholesale distributor in a State who engages in wholesale distributions of prescription drugs in interstate commerce must be licensed by the State licensing authority in accordance with that part before engaging in them.

The statute directs FDA to set national licensing standards by regulation (21 U.S.C. 360eee-2), and a final wholesale distributor regulation takes effect 2 years after publication. FDA proposed standards on February 4, 2022 (87 FR 6708), and the proposal would replace Part 205 in its entirety. The HHS regulatory agenda of August 14, 2026 (91 FR 52992 to 53002) lists a final rule for June 2028, a projection and not a commitment.

Is a third-party logistics provider a wholesale distributor?

Not if it meets the statutory 3PL definition and never assumes an ownership interest in the product it handles. A 3PL provides or coordinates warehousing or other logistics for a product in interstate commerce for a manufacturer, wholesale distributor or dispenser, without owning the product or having responsibility to direct its sale or disposition (21 U.S.C. 360eee(22)). Section 353(e)(5) says such an entity is not required to obtain a wholesale distributor license if it never assumes an ownership interest in the product it handles, and section 360eee-4(b)(2) says “No State shall regulate third-party logistics providers as wholesale distributors.” Licensing timing is subject to the transition below.

Under 21 U.S.C. 360eee-1(a)(7), until the effective date of the 3PL licensing regulations under section 360eee-3, a 3PL is considered “licensed” under section 360eee(9)(B) unless the Secretary has made a finding that it does not use good handling and distribution practices and publishes notice. Section 360eee-3(a) ties each facility’s license from the State it ships from, or from the Secretary if that State has no licensure requirement, to the regulations promulgated under subsection (d); for interstate distribution it adds the State distributed into if that State licenses 3PLs that distribute drugs into it and the Secretary has not licensed the 3PL as described in paragraph (1)(B). Counsel assesses State requirements separately, including for a business that sometimes takes title.

What does 21 CFR Part 205 say?

Part 205 sets minimum standards, terms and conditions for State licensing of persons who engage in wholesale distributions in interstate commerce of prescription drugs (205.2). Wholesale distribution means distribution of prescription drugs to persons other than a consumer or patient, with ten listed exclusions (205.3(f)); the statute has its own definition and exclusions (21 U.S.C. 353(e)(4)), and counsel reads both. Part 205 does not use the term 3PL.

Who needs it and what triggers it?

This service, part of IHS compliance services and compliance program development, is for owners preparing to start operations or assess a new distribution activity. Typical triggers:

• A start-up distributor is about to ship; 205.4 and 21 U.S.C. 353(e)(1)(A) call for the license first.
• A logistics provider will hold drugs for others and must confirm it fits the 3PL definition and takes no title.
• A pharmacy or health system is moving drugs to persons other than a consumer or patient and must check 205.3(f).

How IHS helps

IHS maps applicable requirements to documents and evidence, then drafts materials for owner and counsel review.

1. Operation check: what the business will do with drugs, to whom, from and into which States, and whether it will own the product.
2. Gap assessment against the applicable requirements counsel identifies; for wholesale distributors, include 21 CFR 205.5, 205.7 and 205.50.
3. Drafting of procedures, security checklist, records plan and responsible-persons list.
4. Application content for the State form the owner identifies.
5. Mock review of the premises plan and sample records.

The owner supplies facility and ownership facts, the State form and fee, counsel’s view of State law, and every filing. The federal text sets minimums, not any State’s forms, so IHS drafts to the State text counsel confirms. IHS does not file with, call or correspond with a State licensing authority or FDA, and gives no legal advice.

What to have ready

The Part 205 items below concern wholesale distributors, not an automatic federal checklist for 3PLs. References to 205 are to 21 CFR Part 205 (eCFR file built November 4, 2026); statute references are to U.S. Code text through October 9, 2026. Both were opened November 5, 2026. Counsel identifies the applicable 3PL and State requirements.

• A written description of the activity: which drugs, to whom, from and into which States, and whether the business ever owns them (21 U.S.C. 353(e)(1)(A) and (e)(5)), and the application information in 205.5(a) for each facility and owner.
• A responsible-persons list with each person’s duties and a summary of qualifications (205.50(h)), and personnel with appropriate education and/or experience for positions related to compliance with State licensing requirements (205.7).
• A facility plan with a quarantine area for drugs that are outdated, damaged, deteriorated, misbranded or adulterated, or that are in immediate or sealed secondary containers that have been opened (205.50(a)(3)).
• Security and storage controls, including an after-hours entry alarm and appropriate temperature and humidity recording equipment, devices and/or logs (205.50(b), 205.50(c)(2)); the other facility elements are in the facility answer below.
• Inventory and transaction records set up for the retention, inspection and retrieval conditions in 205.50(f), which the records answer below states.
• Written policies for receipt, security, storage, inventory and distribution, including the four procedures 205.50(g) names; the procedures answer below states their conditions.
• An annual-report calendar: distributors report annually to the Secretary on the Secretary’s schedule their licensing States and license numbers, facility names, addresses and contact information, and trade names. They report significant State or Federal disciplinary actions from the reporting period to the Secretary within a reasonable period and in a reasonable manner, as the Secretary determines (21 U.S.C. 353(e)(2)(A)). Each 3PL facility reports annually to the Secretary on the Secretary’s schedule its licensing State, license number, name, address and trade names (360eee-3(b)).
• Counsel’s written view of how each target State treats the business, and, if the business deals in controlled substances, its registrations (205.50(i)(2)).

If most of these exist only as plans, schedule the free introductory call below before setting an application date.

How it compares

A license, NABP accreditation and controlled substance registration are different things, and a distributor may need more than one.

• License: legal permission to distribute, assessed under State law, 21 U.S.C. 353(e) and 360eee-3, and the transition provisions in 21 U.S.C. 360eee-1(a)(6) and (7).
• NABP Drug Distributor Accreditation: a separate program, covered on IHS’s NABP Drug Distributor page; whether a State or trading partner asks for it depends on that State’s rules and the contract.
• Controlled substances: wholesale distributors dealing in them must register with the appropriate State controlled substance authority and with the Drug Enforcement Administration (DEA) and comply with all applicable State, local and DEA regulations (205.50(i)(2)).

What it costs

Scope depends on the States involved, whether the business is a distributor, a 3PL or both, whether it handles controlled substances, and the number of facilities and amount of existing documentation. The federal sources reviewed provide no State licensing fee schedule, and no State fee schedule was reviewed. Verify current fees with the applicable licensing authority. IHS scopes each engagement after a free introductory call.

What this is not

This is not legal advice. IHS is a consulting firm, not a law firm, and counsel decides which license a business needs in each State.

IHS cannot guarantee a licensing decision.

Sources and how current they are

Reviewed November 5, 2026: current eCFR Part 205 (GPO file built November 4, 2026); U.S. Code text through October 9, 2026; the 2022 proposal and August 2026 agenda cited above. No State law or State fee schedule was reviewed. Later statutory changes are not verified.

Frequently asked questions

What is 21 CFR Part 205?

Part 205 is the federal text giving minimum standards, terms and conditions for State licensing of persons who engage in wholesale distributions of prescription drugs in interstate commerce. The State license is issued under State law.

Who must be licensed as a wholesale drug distributor?

During the statutory transition, 21 U.S.C. 360eee-1(a)(6) treats a wholesale distributor with a valid State-law license as licensed. Section 353(e)(1)(A) describes origin-State or federal licensing and, for interstate distribution, destination-State licensing when that State requires it; counsel assesses the State requirements.

Is a third-party logistics provider a wholesale distributor?

A 3PL provides or coordinates interstate warehousing or logistics for a manufacturer, wholesale distributor or dispenser without owning the product or having responsibility to direct its sale or disposition (21 U.S.C. 360eee(22)). A qualifying entity that never assumes ownership is not required to obtain a wholesale-distributor license (section 353(e)(5)). Its 3PL licensing status is subject to the transition in section 360eee-1(a)(7).

What would FDA’s proposed national licensing rule change?

FDA’s February 4, 2022 proposal would establish national licensing standards for prescription-drug wholesale distributors and 3PLs and replace Part 205 in its entirety. The August 14, 2026 agenda projects a final rule in June 2028; that is not an effective date or a commitment.

What must a distributor’s facility have?

Section 205.50(a) requires suitable size and construction for cleaning, maintenance and operations; adequately designed storage areas; the specified quarantine area; cleanliness; and freedom from infestation. Paragraph (b) requires controlled access, a lighted perimeter, authorized-personnel entry to drug areas, an after-hours alarm and theft and diversion protection, including against computer or record tampering when appropriate.

How long must records be available?

Section 205.50(f)(2) requires inventories and records to be available for inspection and photocopying by authorized Federal, State or local law enforcement officials for 3 years after creation. Under paragraph (f)(3), on-site or immediately electronically retrievable records must be readily available for authorized inspection; centrally stored records not electronically retrievable must be available for inspection within 2 working days of such an official’s request.

What written procedures are required?

Section 205.50(g) requires written policies, maintained and followed, for receipt, security, storage, inventory and distribution, including losses or thefts and inventory correction. Four procedures are named: oldest approved stock first (temporary, appropriate deviations permitted), recalls and withdrawals, facility crises, and segregating outdated drugs for return to the manufacturer or destruction, with disposition records kept 2 years after disposition.

What does IHS prepare, and does it deal with the licensing authority?

IHS drafts the application content, procedures, checklists and records plan, and runs a mock review. IHS does not submit anything to, call or correspond with a State licensing authority or FDA. The owner files and answers, with counsel.